📄 pharmacology and toxicology

Inhibition of NSD1 by 5-O-Sulfamoyl Adenosine improved 5-FU sensitivity by suppressing cancer cell proliferation and xenograft tumor growth

The study demonstrates that 5-O-sulfamoyl adenosine (5-SA) inhibits the oncoprotein NSD1 to suppress cancer cell proliferation and tumor growth, while simultaneously enhancing the sensitivity of cancer cells and xenograft tumors to 5-fluorouracil (5-FU) through synergistic effects.

Original authors: RAFIQ, Z., Tikoo, K.

Published 2026-06-12

📖 3 min read☕ Coffee break read

CC BY 4.0

Original authors: RAFIQ, Z., Tikoo, K.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Imagine your body's cells are like a bustling city. For this city to function, it needs strict rules about when to build new buildings (cell division), when to renovate, and when to tear down old structures (cell death). In a healthy city, these rules are written in a special instruction manual called epigenetics.

However, in some cancers, a specific "foreman" named NSD1 goes rogue. Instead of following the rules, this foreman starts rewriting the instructions to tell the cells to multiply uncontrollably and ignore safety checks. This leads to a chaotic city that grows out of control—a tumor.

Here is how the researchers tackled this problem, using simple analogies:

1. Finding the Right Key

The scientists knew they needed to stop this rogue foreman (NSD1). They had a list of potential "keys" (molecules) that might fit into the foreman's lock and shut him down. Using a digital simulation (like a virtual key test), they found a very promising candidate called 5-O-Sulfamoyl Adenosine, or 5-SA for short.

They compared 5-SA to another molecule called SAC (which is like a standard, off-the-shelf key). The test showed that 5-SA was a much tighter fit. It was about twice as effective at blocking the foreman's work compared to SAC.

2. Turning Off the Lights in the Cancer Cells

Once they used 5-SA to block NSD1, the chaos in the "city" started to calm down:

The Manual Gets Erased: The cancer cells stopped producing the rogue foreman (less NSD1 protein).
The Instructions Stop: Specifically, the chemical "stamps" that tell the cells to keep growing (called H3K36me2) stopped being applied.
The City Halts: Without these growth instructions, the cancer cells stopped multiplying, stopped moving around to invade other areas, and even started a self-destruct sequence (apoptosis).

3. The Power of Teamwork (5-SA + 5-FU)

The researchers also tested a common cancer drug called 5-FU. Think of 5-FU as a standard police officer trying to stop the bad guys. On its own, it works, but the bad guys are tough.

However, when they sent in 5-SA (the key that locks the foreman's office) alongside the police officer (5-FU), the result was much stronger. It wasn't just two people working side-by-side; it was like the police officer suddenly had a superpower. The combination made the cancer cells much more sensitive to the drug, stopping them far more effectively than either one could alone.

4. Testing in the Real World (The Mouse Model)

To see if this worked outside the lab, they tested it on mice with prostate cancer tumors.

Solo Effort: Giving just 5-SA slowed down the tumor growth.
Team Effort: Giving both 5-SA and 5-FU together was a game-changer. The tumors shrank significantly more, and the mice lived longer than in any other group.

The Bottom Line

This study claims that for the first time, they have shown that using 5-SA to lock down the rogue NSD1 foreman makes cancer cells much more vulnerable to the drug 5-FU. By stopping the cancer's internal instruction manual from being rewritten, they were able to slow down tumor growth and help the animals survive longer.

Technical Summary

Problem Statement
Epigenetic dysregulation plays a critical role in cancer pathogenesis by altering cell-cycle kinetics, differentiation, apoptosis, and migration. Specifically, Nuclear receptor-binding SET Domain (NSD) histone methyltransferases have emerged as a family of oncoproteins characterized by aberrant expression in various malignancies. Among these, NSD1 is identified as a potential therapeutic target due to its strong correlation with poor prognosis and tumorigenesis. Despite its clinical relevance, there is a need for effective small-molecule inhibitors that can modulate NSD1 activity to suppress cancer progression and enhance the efficacy of existing chemotherapeutic agents.

Methodology
The study employed a multi-stage approach combining computational biology, biochemical assays, and in vivo models:

Target Validation and Screening: The authors utilized structure-based virtual screening against NSD1, evaluating candidate molecules based on docking scores and MMGBSA $\Delta G_{bind}$ calculations.
Hit Identification: From the screening, 5-O-sulfamoyl adenosine (5-SA) was selected as a primary hit. It was compared against S-Adenosyl-l-Cysteine (SAC), a structural analog of the natural cofactor S-Adenosyl-l-Methionine (SAM), to assess inhibitory potency.
In Vitro Characterization:
- Enzymatic Assays: IC50 values for 5-SA and SAC against NSD1 were determined.
- Cell Viability: The cytotoxic effects of 5-SA were evaluated on DU145 (prostate) and HepG2 (liver) cancer cell lines.
- Molecular Mechanism: The study assessed changes in NSD1 RNA and protein expression, as well as the downstream effect on histone H3 lysine 36 dimethylation (H3K36me2).
- Phenotypic Assays: Cell proliferation, migration, cell cycle distribution, and apoptosis induction were analyzed.
- Combination Therapy: The interaction between 5-SA and 5-Fluorouracil (5-FU) was investigated to determine if 5-SA could sensitize cancer cells to 5-FU.
In Vivo Validation: A xenograft model of prostate cancer was established to evaluate tumor growth kinetics and animal survival following treatment with 5-SA alone and in combination with 5-FU.

Key Results

Inhibitory Potency: 5-SA demonstrated superior inhibitory activity against NSD1 compared to SAC, with IC50 values of 53.819 $\mu$ M and 115.003 $\mu$ M, respectively.
Cytotoxicity: 5-SA significantly reduced cell viability in DU145 and HepG2 cells, yielding IC50 values of 198 $\mu$ M and 168.3 $\mu$ M, respectively.
Molecular Impact: Treatment with 5-SA led to a reduction in both RNA and protein levels of NSD1. Consequently, this downregulation prevented the dimethylation of H3K36 (H3K36me2), a key epigenetic mark associated with active transcription.
Cellular Phenotypes: The compound impeded cell proliferation and migration, induced cell cycle arrest, and triggered apoptosis.
Synergistic Effect: 5-SA potentiated the anticancer activity of 5-FU. In the xenograft model, while 5-SA alone reduced tumor growth kinetics, the combination of 5-SA and 5-FU resulted in a synergistic reduction in tumor growth and improved animal survival rates.

Significance and Claims
The paper claims to report for the first time that 5-O-sulfamoyl adenosine (5-SA) mediates the inhibition of NSD1, thereby enhancing tumor sensitivity to 5-FU. The study establishes 5-SA as a viable candidate for improving tumor growth control and progression outcomes through the dual mechanism of direct NSD1 suppression and chemosensitization. The findings suggest that targeting NSD1 with 5-SA offers a promising strategy to overcome resistance or improve the efficacy of standard chemotherapy regimens like 5-FU in prostate and liver cancers.